Sri Budhi Rianawati, Ria Damayanti, Harun Al Rasyid, Nyoman Artha Megayasa
  MNJ, pp. 104-108  


Background: Vascular dementia is a cognitive decline with functional deterioration caused by cerebrovascular disease. It is the second leading cause of dementia. A number of screening questionnaires and models have been developed to help in assessing cognitive function and activity daily living (ADL) in patients with dementia. Mini Mental State Examination (MMSE), Clock Drawing Test (CDT) and Barthel Index are instruments to evaluate cognitive function and ADL of vascular dementia patients.

Objective: To determine the role of achetylcholine-esterase inhibitor therapy on cognitive function and ADL in patients with vascular dementia in Saiful Anwar General Hospital.

Methods: This study is an analytical study assessing the improvement of cognitive function and ADL of patients with vascular dementia after administration of acethylcholine-esterase inhibitor by assessing the MMSE, CDT and Barthel Index scoring in 1, 3, 6 and 12 month period consecutively.

Results: From 15 study subjects, individuals who have been given treatment for 12 months consecutively have the highest increase in MMSE and CDT whilst for Barthel Index has shown highest improvement in one month period.

Conclusion: The administration of acetylcholine-esterase inhibitor drugs has the potential to improve and maintain cognitive function and improve ADL. The limited number of study subjects and the many confounding factors that we did not evaluate were the drawbacks of this study. The results of this study cannot be generalized to all patients with vascular dementia and only apply to 15 patients who were the subjects of this study.


Vascular Dementia, MMSE, CDT, Barthel Index, Acetylcholine-esterase Inhibitor

Full Text:



World Health Organization. Key Messages The Prevalence Of Dementia Worldwide The Incidence Of Dementia Worldwide The Epidemiology And Impact Of Dementia Current State And Future Trends. 2017 [cited 2019 Dec 27]; Available from:

Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement [Internet]; 2013 Jan 1 [cited 2018 Feb 27];9(1):63-75.e2. Available from:

Pariama AM, Ranimpi YY, Setiawan A. Subjective Well-Being and Healthy Behavior of Elderly With Dementia Alzheimer’S (a Phenomenological Study). MNJ (Malang Neurol Journal); 2020. 6(2):82–7.


Iadecola C. The Pathobiology of Vascular Dementia. Neuron. 2013;80(4):844–66.

Iemolo F, Duro G, Rizzo C, Castiglia L, Hachinski V, Caruso C. Pathophysiology of vascular dementia. Immun Ageing [Internet]; 2009 Nov 6 [cited 2018 Feb 25].6(1):13. Available from:

Samuels MA, Ropper AH. Samuels’s Manual of neurologic therapeutics; 2017. 728. ISBN: 978-1-49-636031-1

Rivarti AW, Herawati L, Hidayati HB. Exercise Prevents Age-Related Memory Decline: the Role of Neurotrophic Factors. MNJ (Malang Neurol Journal); 2020. 6(2):88–94.


Luttenberger K, Schmiedeberg A, Gräßel E. Activities of daily living in dementia: revalidation of the E-ADL test and suggestions for further development. BMC Psychiatry [Internet]; 2012 Dec 23 [cited 2018 Feb 27];12(1):208. Available from:

O’Bryant SE, Humphreys JD, Smith GE, Ivnik RJ, Graff-Radford NR, Petersen RC, et al. Detecting dementia with the mini-mental state examination in highly educated individuals. Arch Neurol [Internet]; 2008 Jul [cited 2018 Feb 27]. 65(7):963–7. Available from:

Wang P, Shi L, Zhao Q, Hong Z, Guo Q. Longitudinal changes in clock drawing test (CDT) performance before and after cognitive decline. PLoS One [Internet]. 2014 [cited 2018 Feb 27];9(5):e97873. Available from:

Sheehan B. Assessment scales in dementia. Ther Adv Neurol Disord [Internet]; 2012 Nov [cited 2018 Feb 27].5(6):349–58. Available from:

Lastri DN, Alwahdy AS. Clinical and Radiologic Approach To Probable Mixed Dementia (Vascular Dementia and Progressive Supranuclear Palsy). MNJ (Malang Neurol Journal); 2020. 6(1):47–50.


Kalaria RN. Neuropharmacology The pathology and pathophysiology of vascular dementia. Neuropharmacology; 2018. 134:226–39.

DOI: 10.1016/j.neuropharm.2017.12.030

Román GC, Salloway S, Black SE, Royall DR, DeCarli C, Weiner MW, et al. Randomized, Placebo-Controlled, Clinical Trial of Donepezil in Vascular Dementia. Stroke; 2010. 41(6):1213–21.

DOI: 10.1161/STROKEAHA.109.570077

Black S, Román GC, Geldmacher DS, Salloway S, Hecker J, Burns A, et al. Efficacy and tolerability of donepezil in vascular dementia: Positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke; 2003. 34(10):2323–30.

DOI: 10.1161/01.STR.0000091396.95360.E1

Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, et al. Donepezil in vascular dementia: A randomized, placebo-controlled study. Neurology; 2003. 61(4):479–86.

DOI: 10.1212/01.wnl.0000078943.50032.fc

Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane Database Syst Rev; 2004. (1). DOI: 10.1002/14651858.CD004395.pub2

Baskys A, Hou AC. Vascular dementia: pharmacological treatment approaches and perspectives. Clin Interv Aging; 2007. 2(3):327–35. Avalaible form:

American Psychiatric Association. Task Force on DSM-IV. Diagnostic and statistical manual of mental disorders : DSM-IV-TR. American Psychiatric Association; 2000. 943 p. Avalaible form:

Sadock BJ, Kaplan HI, Sadock VA. Kaplan & Sadock’s synopsis of psychiatry : Behavioral sciences/clinical psychiatry. Wolter Kluwer/Lippincott Williams & Wilkins; 2007. 1470 p. ISBN: 13:978-81-89960-37-7

Bourgeois MS, Hickey EM (Ellen M. Dementia : from diagnosis to management : A functional approach. Psychology Press; 2009. 429 p.


Vinters H V. Review: Vascular dementia : Clinicopathologic and genetic considerations; 2018. 247–66. DOI: 10.1111/nan.12472


  • There are currently no refbacks.